retatrutide ly3437943 glp-1 gip glucagon LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Retatrutide vs Tirzepatide & Semaglutide

This resulted in an average weight loss of 11 pounds, mostly from body fat

Meetup: This social media platform offers thousands of opportunities for people seeking informal weight loss support, including fitness buddies

This approach has not been formally studied for retatrutide but aligns with the pharmacological logic and clinical precedent from the broader class

These medications tend to share a similar side effect profile

Don't Forget Lifestyle Factors Nutrition is important, but other habits also matter

Your clinician may need to adjust your diabetes medication doses when starting GLP-1 therapy - which is why full disclosure of your medication list is mandatory, not optional